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Flavivirus NS3 helicaseThe interferon-inducible 2′,5′-oligoadenylate synthetase 1b (Oas1b) protein inhibits West Nile virus (WNV)
infection by preventing viral RNA (vRNA) accumulation in infected cells. Serial passage of WNV in Oas1b-
expressing mouse cells selected a virus variant with improved growth capacity. Two major amino acid
substitutions were identiﬁed in this Oas1b-resistant WNV variant: NS3-S365G in the ATPase/helicase
domain of NS3 and 2K-V9M in the C-terminal segment of NS4A. To assess their effect on antiviral activity of
Oas1b, the NS3 and 2K mutations were engineered into an infectious WNV cDNA clone. The NS3 mutation
alters requirement of ATP for ATPase activity and attenuates Oas1b-mediated suppression of vRNA
accumulation. However, growth of NS3-mutant virus remains impaired in Oas1b-expressing cells. Only the
2K-V9M mutation efﬁciently rescued viral growth by promoting vRNA replication. Thus, WNV resistance to
Oas1b antiviral action could be attributed to the 2K-V9M substitution with a potential role of NS3-S365G
through rescue of vRNA accumulation.aires Flavivirus-Hôtes, Institut
e.
rès).
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West Nile virus (WNV), a member of the Flavivirus genus (family
Flaviviridae), is an arthropod-borne pathogen infecting primarily
avian species but also humans via mosquitoes. This zoonotic virus is
endemic in many parts of Africa, Asia, Europe, the Middle-East and
more recently North America (Artsob et al., 2009). Although
asymptomatic in a majority of cases, WNV infection has been
associated with neurotropic human manifestations including
meningo-encephalitis and acute ﬂaccid paralysis (Davis et al., 2006;
Hayes et al., 2005).
WNV contains a positive single-stranded (ss) RNA genome
encoding a polyprotein that is processed into three structural proteins
(capsid C, membrane precursor prM and envelope E) and seven
nonstructural (NS) proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B and
NS5) by cellular and viral-encoded proteases (Brinton, 2002). The full-
length NS3 protein is a multifunctional viral enzyme that exhibits
serine protease activity from its N-terminal domain (NS3pro) and
ATPase and helicase activity from its C-terminal domain (NTPase/
helicase) (Lindenbach, Thiel, and Rice, 2007). During viral replication,
the role of the NS3 helicase is to separate the double-stranded RNAintermediates formed during viral replication or disrupt secondary
structures formed by the ssRNA template (Frick, 2007; Lescar et al.,
2008). The small, hydrophobic NS4A protein, which is associated to
the ER membrane, is suggested to act as a cofactor of NS3 regulating
ATPase activity in an energy-conserving manner (Shiryaev et al.,
2009; Umareddy et al., 2006). Its C-terminal 23-amino acid residues,
designated 2K peptide, form a transmembrane domain that acts as
signal sequence for the translocation of NS4B into the lumen of the
endoplasmic reticulum (ER) (Miller et al., 2007). The cleavage of the
NS4A-2K-NS4B occurs by the NS2B-NS3pro protease at the NS4A-2K
junction and by the host signalase in the ER lumen at the 2K-NS4B
junction (Lin et al., 1993). Processing of NS4A/2K was shown to
induce rearrangement of intracellular membranes, which may form a
scaffold for the viral replication complex (Miller et al., 2007;
Roosendaal et al., 2006). Recent data implicate the 2K peptide in
vRNA synthesis (Zou et al., 2008, 2009).
A key factor of successful WNV infection is the ability of the virus
to interfere with the innate host immunity mediated by type-I
interferons (IFN-α/β). The IFN-inducible 2′,5′-oligoadenylate synthe-
tases (OAS) contribute to the establishment of an antiviral state
against RNA virus infection (Silverman, 2007). The OAS/RNase L
system is an antiviral decay pathway, which affects viral replication by
activating the endoribonuclease RNase L and inducing vRNA degra-
dation (Samuel, 2002; Zhou et al., 1997). It was recently reported that
genetic variation in human OAS1 is a host genetic risk factor for initial
Fig. 1. Antiviral effect of Oas1b against WNV infection. Induced (−Tet, ﬁlled boxes) and
non-induced (+Tet, open boxes) MEF/3T3.Tet-Off/Oas1b cells (A, B) and MEF/3T3.
Tet-Off/Oas1b/siRNA82 cells (C) were infected with WNV IS-98-ST1, NY99 and WN-
Oas1bR at MOI 1. Tetracycline was removed concomitantly with viral input. At 48 h p.i.,
viral titers in the supernatant were determined by FIA on AP61 cells. Bars denote
standard deviations. The values of two independent experiments were compared
according to Student's t test (⁎⁎p≤0.01, ⁎⁎⁎p≤0.001).
177E. Mertens et al. / Virology 399 (2010) 176–185infection with WNV (Lim et al., 2009). We and others demonstrated
that the murine isoform Oas1b is a critical determinant for genetic
susceptibility to WNV infection in mice (Mashimo et al., 2002b;
Perelygin et al., 2002) Oas1b exerts its antiviral effect on WNV by
preventing vRNA accumulation through an RNase L-independent
pathway (Kajaste-Rudnitski et al., 2005). However, the antiviral
action of Oas1b against WNV becomes progressively attenuated once
virus replication is established in infected cells (Kajaste-Rudnitski et
al., 2005). Such ﬁndings suggest that WNV has the capacity to escape
the antiviral action of Oas1b.
In this report, we sought to identify viral determinants able to
promote resistance of WNV to the Oas1b antiviral pathway. Serial
passage of WNV IS-98-ST1 in mouse ﬁbroblastic cells expressing
Oas1b gave rise to a WNV variant, which displays resistance to the
antiviral effect of Oas1b. The analysis of this WNV variant identiﬁed
two major amino acid substitutions in the NS3 NTPase/helicase
domain and the 2K peptide that promote WNV resistance to the
antiviral effect of Oas1b at the cellular level.
Results
Sensitivity of WNV strains to Oas1b
We recently described an inducible MEF/3T3.Tet-Off/Oas1b cell
line that up-regulates recombinant Oas1b protein expression under
the control of the Tet-Off expression system (Kajaste-Rudnitski et al.,
2005). In presence of a Tetracycline (Tet) repressor, only a
background level of Oas1b mRNA was detected in non-induced
MEF/3T3.Tet-Off/Oas1b cells. Upon withdrawal of Tet, there is a ﬁve-
fold increase in Oas1b mRNA production compared to non-induced
cells. We reported that recombinant Oas1b protein is subjected to
protein degradation by the ubiquitin/proteasome-dependent path-
way preventing its accumulation in induced MEF/3T3.Tet-Off/Oas1b
cells (Kajaste-Rudnitski et al., 2005). To investigate the effect of Oas1b
expression on WNV infection of mouse ﬁbroblastic cells, MEF/3T3.
Tet-Off/Oas1b cells were infected with the Israeli WNV strain IS-98-
ST1 at multiplicity of infection (MOI) 1. To induce Oas1b expression,
Tet repressor was removed concomitantly with virus input as
previously reported (Kajaste-Rudnitski et al., 2005). Uponwithdrawal
of the Tet repressor, there was a 2.5-log reduction of virus progeny
production at 48 h p.i. (Fig. 1A).
To further assess the inhibitory effect of Oas1b on WNV
infection, MEF/3T3.Tet-Off/Oas1b cells were infected at MOI 1
with the North American WNV strain NY99 that was generated
from an infectious cDNA clone (Khromykh et al., manuscript in
preparation). WNV strains IS-98-ST1 and NY99 belong to a distinct
phylogenetic clade in WNV lineage I (Charrel et al., 2003; Lanciotti
et al., 2002) that is associated with increased virulence (Gubler,
2007; Lucas et al., 2004). In mouse cells expressing a background
level of Oas1b, there was no signiﬁcant difference in viral titer
between NY99 and IS-98-ST1 (Fig. 1A, ﬁlled boxes). In response to
Oas1b induction, a comparable degree of inhibition in virus progeny
production was observed (Fig. 1A, open boxes). Thus, neuropatho-
genic Israeli and North American WNV strains display a marked
susceptibility to the antiviral activity of Oas1b. Comparison of WNV
IS-98-ST1 and NY99 382-99 genomes revealed only minor differ-
ences in the NS2A protein and NS3pro domain (Khromykh et al.,
manuscript in preparation), indicating that NY99 virus derived from
the infectious cDNA clone is suitable for studying viral determinants
of WNV resistance to Oas1b.
Production and selection of Oas1b-resistant WNVs
To select WNV variants efﬁciently replicating in mouse cells
expressing Oas1b, WNV strain IS-98-ST1 was serially passaged in
induced MEF/3T3.Tet-Off/Oas1b cells at MOI 1. As a control, passageof WNV was performed on induced MEF/3T3.Tet-Off/Oas1bΔC-term
cells that are incapable of inhibitingWNV infection (Kajaste-Rudnitski
et al., 2005). A total of eight passages in induced MEF/3T3.Tet-Off/
Oas1b cells were performed and the P8 viruses were cloned in these
cells by limiting dilutions. A single virus clone, hereafter named WN-
Oas1bR, displayedmarked resistance to the antiviral action of Oas1b in
induced MEF/3T3.Tet-Off/Oas1b cells.
We examined the capacity of WN-Oas1bR to replicate in MEF/
3T3.Tet-Off/Oas1b cells (Fig. 1B). A minor increase in viral titers was
observed after infection of non-induced MEF/3T3.Tet-Off/Oas1b
cells with WN-Oas1bR compared to IS-98-ST1 (Fig. 1B). Although
WN-Oas1bR did not show complete resistance to Oas1b in induced
MEF/3T3.Tet-Off/Oas1b cells, higher virus titers were recovered
from cell supernatants as compared to IS-98-ST1 (Fig. 1B). This
result suggests that WNV variant WN-Oas1bR has the capacity to
counteract the antiviral activity of Oas1b in infected mouse cells. We
observed that WN-Oas1bR and IS-98-ST1 display comparable
susceptibility to IFN-α action (Supplementary data 1), indicating
that the WNV variant affects the Oas1b antiviral pathway rather
than IFN signaling.
Fig. 2. Analysis of WN-Oas1bR replication in Oas1b-expressing cells. MEF/3T3.Tet-Off/
Oas1b cells were infected with WNV IS-98-ST1 and WN-Oas1bR at MOI 1 for 24 h. (A)
Lysates from induced (−Tet) and non-induced (+Tet) cells infected with either IS-98-
ST1, WN-Oas1bR or mock infected (mock) were immunoblotted using anti-E mAb 4G2.
Mouse β-actin served as an internal control. (B, C) Real-time RT-PCR analysis of vRNA
expression using primers speciﬁc for the E gene from WNV. The 18S rRNA served as
endogenous sequence control. In panel B, induced cells were infected with IS-98-ST1 or
WN-Oas1bR. The relative vRNA expression in cells infectedwith IS-98-ST1 was assigned a
value of 1. In panel C, induced (−Tet) and non-induced (+Tet) cells were infected with
WN-Oas1bR. The relative vRNA expression in non-induced cells was assigned a value of 1.
Bars denote standard deviations. The values of two independent experiments in triplicate
were compared according to Student's t test (⁎p≤0.05, ⁎⁎p≤0.01, ⁎⁎⁎p≤0.001).
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replication in infected MEF/3T3.Tet-Off cells (Kajaste-Rudnitski et al.,
2005), we determined the capacity of WN-Oas1bR to replicate in
infected MEF/3T3.Tet-Off/Oas1b/siRNA82 cells (Fig. 1C). These
Oas1b-expressing cells are stably transfected with pSIREN-RetroQ/
siRNA-82 to down-regulate RNase L expression (Kajaste-Rudnitski et
al., 2005). As shown in Fig. 1C, WN-Oas1bR yields were slightly
increased in non-induced MEF/3T3.Tet-Off/Oas1b/siRNA82 cells as
compared to IS-98-ST1. In response to Oas1b expression, a similar
degree of inhibition in viral titer between IS-98-ST1 and WN-Oas1bR
was observed. Thus, inhibition of endogenous RNase L did not further
rescue WN-Oas1bR in Oas1b-expressing cells. This is consistent with
the assumption that Oas1b exerts its antiviral activity through a RNase
L-independent pathway (Kajaste-Rudnitski et al., 2005).
Molecular basis of WN-Oas1bR resistance to Oas1b
We reported that expression of Oas1b suppresses WNV infection
by restricting the capacity of the virus to accumulate viral proteins in
infected cells (Kajaste-Rudnitski et al., 2005). We investigated
whether the capacity of WN-Oas1bR to circumvent the antiviral effect
of Oas1b was associated with a rescue in viral protein production and
vRNA accumulation. The expression of viral proteins was analyzed by
immunoblotting of cell lysates from WNV-infected MEF/3T3.Tet-Off/
Oas1b cells withmonoclonal antibody (mAb) 4G2 directed against the
ﬂavivirus E protein (Fig. 2A). At 24 h post-infection, a higher level of E
was observed in induced MEF/3T3.Tet-Off/Oas1b cells infected with
WN-Oas1bR compared to parental virus (Fig. 2A, −Tet), indicating
that the Oas1b-mediated inhibition of viral protein synthesis was less
effective forWN-Oas1bR. Also, infectionwithWN-Oas1bR resulted in a
higher accumulation of E in non-induced MEF/3T3.Tet-Off/Oas1b
cells as compared to parental virus (Fig. 2A, +Tet). This suggests that
WN-Oas1bR has improved capability to replicate in mouse ﬁbroblastic
cells.
To determine whether rescue of WN-Oas1bR protein synthesis in
Oas1b-expressing cells was associated with an increase in vRNA
replication, total RNA was extracted from WNV-infected MEF/3T3.
Tet-Off/Oas1b cells and positive-stranded vRNA production was
analyzed by real-time RT-PCR. In cells expressing a background
level of Oas1b, vRNA production by WN-Oas1bR was at least 10-fold
higher than that found in cells infected by IS-98-ST1 (Fig. 2B). Thus,
the improved capacity of WN-Oas1bR to produce viral proteins could
be attributed to enhanced vRNA production. As shown in Fig. 2C, WN-
Oas1bR and IS-98-ST1 displayed a similar sensitivity to the Oas1b-
mediated inhibition of vRNA production. Together, these results
suggest that the ability of WN-Oas1bR to productively infect Oas1b-
expressing mouse cells is attributable to an increased level of vRNA
production rather than antagonism of Oas1b-mediated vRNA
inhibition.
Molecular characterization of WN-Oas1bR
Comparative analysis of genomic RNA from IS-98-ST1 and WN-
Oas1bR identiﬁed six nucleotide mutations (Fig. 3A). Two of these
were silent, the remaining four resulted in amino acid substitutions in
the structural (prM-22 and E-390) and NS (NS3-365 and NS4A-135)
genes (Fig. 3B). The amino acid change Ser to Gly at residue NS3-365
maps to the WNV NS3 ATPase/helicase domain. The amino acid
substitution from Val to Met at residue NS4A-135 maps to position 9
of its C-terminal transmembrane 2K peptide (Fig. 3B). To determine
whether any of the WN-Oas1bR mutations could be attributed to cell
culture adaptation due to repeated passage of WNV on mouse
ﬁbroblastic cells, 10 passages of IS-98-ST1 on induced MEF/3T3.Tet-
Off/Oas1bΔC-term cells were performed, which are incapable of
inhibiting WNV infection (Kajaste-Rudnitski et al., 2005). Direct
sequencing of WN-Oas1bΔC-termP10 viruses at the nucleotide posi-tions where mutations in WN-Oas1bR occurred (Fig. 3A) identiﬁed
only the nucleotide mutation A2135G. This result suggests that the
amino acid substitution from Glu to Gly at the position E-390 arose
during cell culture adaptation. The E-E390G change maps to a
potential integrin-binding motif in the antigenic domain III of the
WNV E protein (Beasley et al., 2005; Chambers et al., 2008). Lee et al.
(2004) reported that mutations occurring in this motif led to
attenuation in neurovirulence through an increased afﬁnity to cell
surface glycosaminoglycans (GAGs). We investigated the effect of the
E-E390G substitution by measuring the residual infectivity of WNV
Fig. 3. Genomic analysis of passagedWNVs. (A)Nucleotidemutations and aminoacid substitutions inWN-Oas1bR andWN-Oas1bΔC-termP10 relative to parental virus IS-98-ST1. n.d.=not
determined. (B) Mapping of the synonymous (open triangles) and non-synonymous (full triangles) changes to the structural and nonstructural regions of WN-Oas1bR.
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control. As determined by FIA, preincubation of WNV with Heparin
signiﬁcantly affected the infectivity of WN-Oas1bR but not IS-98-ST1.
Our data support the hypothesis that amino acid substitution Glu to
Gly at position E-390 enhances the afﬁnity of WNV to GAGs.
The effect of the NS3 mutation on ATPase activity
The NS3-365 substitution of WN-Oas1bR maps to the NS3 NTPase/
helicase domain and has not been described for any WNV strain. To
investigate the effect of the amino acid substitution from Ser to Gly at
position NS3-365 on the ATPase activity of NS3, we expressed soluble
NS3 NTPase/helicase domains (position 182-619) from IS-98-ST1 and
WN-Oas1bR in Escherichia coli. Purity and speciﬁcity of the recombi-
nant NS3 NTPase/helicase domains were veriﬁed by Coomassie
staining (Fig. 5A, left) and immunoblotting using an antibody against
the C-terminal V5 epitope (Fig. 5A, right). Our recombinant NS3
NTPase/helicase constructs do not exhibit helicase activity, consistent
with the ﬁnding that only full-length NS3 molecules exhibit
measurable helicase activity (Feito et al., 2008; Sikora et al., 2008).
We examined the catalytic properties of the NS3 NTPase/helicase
domains of IS-98-ST1 and WN-Oas1bR by measuring the ATPaseFig. 4. Heparin treatment inhibits WN-Oas1bR infectivity. IS-98-ST1 and WN-Oas1bR
were incubated with heparin–sepharose beads (open boxes) and protein-A–sepharose
beads (ﬁlled boxes). Viral titers of the unbound virus fractions were determined by FIA.
Bars denote standard deviations. The values of two independent experiments were
compared according to Student's t test (⁎⁎p≤0.01, ⁎p≤0.05).
Fig. 5. The NS3 mutation of WN-Oas1bR enhances ATPase activity. (A) SDS–PAGE
analysis of puriﬁed NS3 NTPase/helicase domains from IS-98-ST1 and WN-Oas1bR
stained with Coomassie brilliant blue (left) and immunoblotted with anti-V5 antibody
(right). (B) Dose-dependent ATPase activity of the NS3 NTPase/helicase domain from
IS-98-ST1 (closed circle) and WN-Oas1bR (open box). The release of inorganic
phosphate in the presence of the indicated concentrations of ATP was ﬁtted using the
Michaelis–Menten equation. See Materials and methods for details. Km was calculated
using the GraphPad Prism software. Bars denote standard deviations.
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NTPase/helicase proteins showed ATPase activity with similar
maximal turnover rates (Kcat about 1 s−1). Direct comparison showed
that the Km value of the NS3 NTPase/helicase domain from WN-
Oas1bR was about 3-fold lower (1.8±0.5 μM) than that of IS-98-ST1
(5.5±1.7 μM). This result suggests that the Gly residue at position
NS3-365 allows the NS3 NTPase/helicase to perform similar ATPase
activity at lower ATP concentrations.
The role of the 2K mutation in NS4A and NS4B expression
We examined whether the 2K-V9M substitution alters the
expression of NS4A-2K and 2K-NS4B precursors in cells. The C-
terminal transmembrane 2K segment is cleaved fromNS4A during the
processing of the NS4A-NS4B polyprotein intermediate by the viral
NS2B-3 protease. The 2K peptide, which spans the membrane from
the cytoplasm to the ER lumen, is processed from the N-terminus of
NS4B by the host signalase.
HEK-293T cells were transfected with dsRed expression vectors
that encode NS4A-2K and 2K-NS4B precursors fromWN-Oas1bR or IS-
98-ST1 (Fig. 6A). The expression of NS4A-2K and 2K-NS4B proteins,
which carry a C-terminal HA tag, was ﬁrst analyzed by immunoblot-
ting of cell lysates with an antibody directed against the HA epitope. In
transfected cells expressing the NS4A-2K product, there was a single
HA-tagged protein species thatmigrated at the expected size (16 kDa)
of the unprocessed precursor (Fig. 6B). No signiﬁcant change in
expression level or migration proﬁle was observed betweenwild-type
(WT) and mutant NS4A-2K products. In transfected cells expressing
the 2K-NS4B, HA-tagged protein species from 25 to 30 kDa migrated
with the apparent molecular weights of mature NS4B and an
unprocessed 2K-NS4B, respectively (Fig. 6B). The 2K mutation doesFig. 6. Expression and subcellular localization of NS4A-2K and 2K-NS4B precursors. HEK-293
2K-NS4B proteins tagged with a HA epitope at their C-termini. (A) Schematic representatio
antibody. (C, D) Immunoﬂuorescence assay was performed on cells expressing NS4A-2K (C)
ER marker Calreticulin was detected with a polyclonal anti-Calreticulin antibody. Nuclei we
same magniﬁcation of ×63 is used throughout.not alter the expression level or processing of the 2K-NS4B precursor.
Together, these results suggest that the 2K-V9M change has no
signiﬁcant effect on the expression of the NS4A-2K and 2K-NS4B
precursors.
To further analyze the effect of the 2K mutation, we examined the
subcellular distribution of individual NS4A-2K and 2K-NS4B proteins
by IF analysis (Figs. 6C and D). Transfected HEK-293T cells expressing
the NS4A-2K product were ﬁxed and incubated with different
concentrations of Triton X-100 to permeabilize either intracellular
membranes (0.1% detergent) or the plasma membrane alone (0.01%)
(P. Lazarow, personal communication) (Fig. 6C). At lowest concen-
tration of detergent, no staining of the ER marker Calreticulin was
observed (data not shown). Also, there was no positive staining with
antibody against the HA tag indicating that the C-terminal HA tag of
NS4A-2K is presumably addressed towards the ER lumen. At 0.1% of
Triton X-100, NS4A-2K was clearly detected in distinct dot-like
structures in the ER. A comparable staining pattern was observed
between the WT and mutant NS4A-2K products. Thus, the G6871A
change does not alter the subcellular localization of the C-terminal
transmembrane 2K segment of NS4A. Also, a similar pattern of
ﬂuorescence was observed in cells expressing either WT or mutant
2K-NS4B proteins (Fig. 6D). Taken together, these results suggest that
the G6871A change does not alter the processing and intracellular
localization of the NS4A-2K-NS4B precursor.
The role of the NS3 and 2K mutations in WNV resistance to Oas1b
To further analyze the role of the NS3 and 2K mutations in WNV
resistance to Oas1b, the corresponding changes either alone or in
combination were introduced into an infectious cDNA clone derived
from a NY99 strain (Khromykh et al., manuscript in preparation). ViralT cells were transiently transfected for 48 h with dsRed vectors expressing NS4A-2K and
n of the constructs. (B) Immunoblot assay on cell lysates was performed using anti-HA
and 2K-NS4B (D) proteins using FITC-conjugated rat monoclonal anti-HA antibody. The
re stained with DAPI. Arrowheads indicate HA-tagged proteins in transfected cells. The
Fig. 8. Effects of the NS3 and 2K mutations on viral growth in Oas1b-expressing cells.
Induced (closed boxes) and non-induced (open boxes) MEF/3T3.Tet-Off/Oas1b cells
were infected with individual WNV NY99 at MOI 1. At 48 h p.i., viral titers in the
supernatant were determined by FIA. Bars denote standard deviations. The data are
representative of two separate experiments. The p values of mutant viruses versus
NY99 in induced cells were determined according to Student's t test when comparing
the viral titer of mutant NY99 to WT NY99 (⁎p≤0.05).
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to generate individual mutant viruses NY99/NS3-S365G and NY99/
2K-V9M and double mutant virus NY99/NS3+2K. There was no
change in plaque size and morphology between mutant and NY99wt
viruses (Supplementary data 2). Zou et al. (2008) reported that the
2K-V9M substitution confers resistance against the ﬂavivirus inhibitor
lycorine. As a control, we showed that NY99/2K-V9M and NY99/
NS3+2K carrying the 2K mutation display resistance to the inhibitory
effect of lycorine as compared to NY99wt (Supplementary data 3).
To evaluate the ability of the NS3 and 2K mutation to control
antiviral activity of Oas1b, the production of intracellular vRNA was
assayed inWNV-infected non-induced (Fig. 7A) and induced (Fig. 7B)
MEF/3T3.Tet-Off/Oas1b cells by real-time RT-PCR analysis. We
observed a marked increase in vRNA accumulation in mouse cells
infected with NY99/2K-V9M as compared to NY99wt (Fig. 7A). This
result is consistent with the notion that the Val to Met substitution at
position 2K-9 enhances WNV replication (Zou et al., 2008). There was
a ∼1 log increase in viral titer recovered from induced MEF/3T3.Tet-
Off/Oas1b cells infected with the 2K-mutant as compared to NY99wt
(Fig. 8). However, the 2K-mutant and NY99wt showed a comparable
decrease in vRNA accumulation in Oas1b-expressing cells (Fig. 7B).
We observed that the NS3 mutation resulted in increased vRNA
accumulation in Oas1b-expressing cells as compared to the NY99wt
(Fig. 7B), although this increased RNA production did not lead to a
corresponding increase in production of secreted virus (Fig. 8).Fig. 7. Viral RNA production in Oas1b-expressing cells infected with WT and mutant NY99 vi
legend of Fig. 2. Induced and non-induced MEF/3T3.Tet-Off/Oas1b cells were infected
NY99/2K+NS3 at MOI 1 for 24 h. In panel A, the relative level of vRNA production in non-ind
(+Tet) and induced (−Tet) cells were infected with individual WT and mutant NY99 viruses.
standard deviations. The values of two independent experiments in triplicate were comparedAnalysis of vRNA accumulation (Fig. 7B) and progeny virus production
(Fig. 8) showed the inability of NY99/NS3+2K to replicate efﬁciently
in induced MEF/3T3.Tet-Off/Oas1b cells. Given that growth of theruses. Real-time RT-PCR analysis of vRNA production was performed as described in the
with parental WNV NY99wt and mutant NY99/NS3-S365G, NY99/2K-V9M and
uced cells infected with NY99wt virus was assigned a value of 1. In panel B, non-induced
The relative vRNA production in non-induced cells was assigned a value of 1. Bars denote
according to Student's t test (⁎⁎⁎p≤0.001, ⁎⁎p≤0.01, ⁎p≤0.05, n.s.=not signiﬁcant).
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(Fig. 1A, Supplementary data 3), we cannot rule out the possibility
that occurrence of both NS3-S365G and 2K-V9M changes in the
context of NY99 negatively interferes with the efﬁciency of WNV
replication. Taken together, these results suggest that the 2Kmutation
is a critical determinant for WNV resistance to the antiviral action of
Oas1b by promoting vRNA accumulation. It is likely that the NS3-
S365G substitution contributes to Oas1b resistance of WNV through
the rescue of vRNA production in mouse cells expressing Oas1b.
Discussion
The rapid initiation of host cell defenses mediated by type-I IFNs is
essential for protection against WNV infection (Samuel and Diamond,
2006). There is mounting evidence that IFN-stimulated OAS genes are
responsible for the establishment of an antiviral state against WNV
infection (Silverman, 2007). A mouse model of WNV-induced
encephalitis revealed a key role for IFN-inducible Oas1b in protective
innate immunity to WNV (Mashimo et al., 2002a; Perelygin et al.,
2002). In an effort to resolve the molecular basis of the antiviral effect
of Oas1b, we demonstrated that mouse Oas1b inhibits WNV
replication by preventing vRNA accumulation in infected cells
through a RNase L-independent antiviral pathway (Kajaste-Rudnitski
et al., 2005).
Recent attention has focused on the ability of WNV to counteract
the antiviral innate immunity. Viral IFN antagonists may be
responsible for this effect by inhibiting type-I IFN signaling (Diamond
and Madhani, 2009; Suthar et al., 2009). Deciphering the interactions
between WNV and Oas1b and understanding the molecular basis for
viral diversity will provide insights into how WNV circumvents
antiviral action of type-I IFN. The purpose of this study was to identify
viral determinants required to promote WNV resistance to the Oas1b
antiviral pathway. We report the characterization of a WNV variant,
WN-Oas1bR, produced by serial passage in Oas1b-expressing cells of
the neurovirulent WNV strain IS-98-ST1 (Lucas et al., 2004). WN-
Oas1bR displays the phenotypic characteristics of resistance to the
Oas1b antiviral pathway. Replication of WN-Oas1bR was associated
with a marked increase in vRNA production in infected mouse cells as
compared to the parental virus. Our data suggest that the rescue of
viral growth in Oas1b-expressing cells did not arise from an
impairment of Oas1b-mediated vRNA inhibition, but rather from a
marked increase in overall RNA production.
Whole-genome sequencing of WN-Oas1bR identiﬁed six nucleo-
tide mutations in the coding region, two of which encoded amino acid
substitutions in the structural proteins (prM-22 and E-390) and two
in the nonstructural proteins (NS3-365 and 2K-9) relative to parent
IS-98-ST1. We found that the amino acid change E390G in the E
protein was associated with cell culture adaptation. WN-Oas1bR
displays an increased GAG-binding activity that is most likely a
consequence of the E-E390G substitution as reported by Lee et al. (Lee,
Hall, and Lobigs, 2004). Given that increased dependence on GAG was
associated with loss of neuroinvasiveness (Lee, Hall, and Lobigs,
2004), we evaluated the neuropathogenicity of WN-Oas1bR in adult
BALB/c mice. When WN-Oas1bR was inoculated intradermally, WNV
variant WN-Oas1bR was attenuated for neuroinvasiveness in mice as
compared to the parental virus (Supplementary data 4). The
augmented afﬁnity for GAG might account for the attenuation of the
neuroinvasive phenotype of WN-Oas1bR. A mutation in prM-29 was
reported as the only change in the structural proteins after serial
passage of dengue-2 virus 16681 in dog ﬁbroblasts to obtain the live-
attenuated PDK-53 virus (Butrapet et al., 2000). It remains to be
determined whether the prM-V22G substitution contributes to the
attenuated phenotype of WN-Oas1bR.
The analysis of theWNV variant WN-Oas1bR identiﬁed a Ser to Gly
substitution at residue NS3-365 and a Val to Met change at residue
2K-9. The NS3-S365G substitution maps to the NTPase/helicasedomain, and this change has not been previously described in any
WNV strain. NS3 is a DEAH/D box helicase within helicase
superfamily 2 and the NS3-S365G change occurs in the conserved
H4 motif encompassing NS3 residues 362–367 (Mancini et al., 2007).
Mechanistic analysis demonstrated that the NS3-S365G substitution
lowers the requirement of ATP for its ATPase activity. Whether the
S365G substitution allows the NS3 helicase to sustain the unwinding
rate of vRNA under conditions of ATP deﬁciency is a critical issue that
remains to be investigated. It was reported that a single amino acid
substitution in the NS3 helicase was sufﬁcient to alter neurovirulence
ofWNV (Brault et al., 2007). In vivo experiments will be undertaken to
analyze the effect of the NS3-S365G substitution on the neuropatho-
genicity of WNV.
The function of the hydrophobic 2K peptide that spans the ER
membrane between NS4A and NS4B remains largely unknown. It is
believed that it acts as signal sequence for the translocation of NS4B
into the ER lumen. It is removed from the N-terminus of NS4B by a
host ER signalase. Our data showed that the Val to Met substitution at
position 2K-9 does not alter the subcellular localization and the
processing of the NS4A-2K or 2K-NS4B precursors. Interestingly, Zou
et al. (2008) reported that the V9M substitution in the 2K peptide
conferred WNV resistance to the ﬂavivirus inhibitor lycorine by
enhancing vRNA replication. The 2K mutation might alter its
interaction with host factors involved in vRNA synthesis through an
unknown mechanism (Zou et al., 2009).
The fact that the NS3 and 2K mutations potentially enhance viral
replication prompted us to study their effects on Oas1b-mediated
inhibition of WNV by engineering the respective mutations into an
infectious cDNAcloneofWNV. TheNS3-S365Gand the2K-V9Mmutants
were examined for their resistance to Oas1b in infected cells. The 2K-
mutant was highly susceptible to Oas1b-mediated vRNA inhibition.
However, viral growth analysis showed that 2K-mutant virus generates
higher viral titers inOas1b-expressing cells than theWTvirus. Oneof the
critical issues to be addressed in the future relates to exact mechanisms
by which the 2K-V9M substitution enables WNV resistance to antiviral
action of Oas1b. Additional studies will be undertaken to determine if
protection by the 2K mutation was a direct consequence of increased
overall vRNA production using WNV replicons.
In response to Oas1b expression, the NS3-mutant showed a
marked resistance to Oas1b-mediated vRNA inhibition, but the rescue
of vRNA production was not reﬂected in increased viral growth. These
results suggest that the capability of WN-Oas1bR to grow in Oas1b-
expressing cells might be attributed to the single amino acid
substitution in the 2K peptide. Although resistance assays demon-
strated the inefﬁciency of NS3-mutant virus to productively infect
Oas1b-expressing cells, an increased vRNA accumulation was ob-
served in these cells as compared to WT virus. It is presumed that the
NS3-S365G substitution enhances vRNA replication by consuming
lower quantities of ATP in the host cell.
We asked whether enhancement of vRNA replication mediated by
the NS3 NTPase/helicase mutation acts in synergy with the 2K
mutation. Unexpectedly, mutant WNV NY99 carrying both NS3 and
2K mutations was ineffective to circumvent the Oas1b-mediated
inhibition of viral growth. A possible explanation could be that the
two remaining nucleotidemutations in the E and NS1 proteins ofWN-
Oas1bR are also involved in the attenuated antiviral effect of Oas1b
against WNV. The involvement of synonymous nucleotide changes in
the phenotypic characteristics of Oas1bR requires further analysis.
The Val to Met substitution at position 2K-9 seems to act as a key
determinant of WNV resistance to the Oas1b antiviral pathway. We
plan to extend our study on the role of the 2K mutation in WNV
resistance to Oas1b by introducing the corresponding amino acid
change into WNV strain IS-98-ST1. To this end, we have undertaken
experiments to generate a full-length cDNA clone of IS-98-ST1. One of
the critical issues to be addressed in the future relates to the
mechanisms by which the 2K-V9M substitution contributes to rescue
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membrane-associated 2K peptide in the efﬁciency of viral growth,
either by forming the framework for the viral replication complex or
through processing of the NS4A-2K-NS4B precursor mediated by the
viral protease and a host signalase (Roosendaal et al., 2006). Recent
data suggest that NS4A acts as a cofactor of NS3 to modulate helicase
activity (Shiryaev et al., 2009). We cannot rule out the possibility that
the 2K mutation facilitates the NS2B/3 protease-mediated cleavage at
the NS4A-2K junction leading to an enhanced NS3 helicase activity.
Previous reports suggested that NS4A and NS4B might contribute to
the control of IFN-α/β signaling byWNV (Muñoz-Jordán et al., 2005).
Given that we do not observe any change in IFN-α sensitivity between
the Oas1b-resistant WNV variant and the parental virus, it seems
unlikely that the 2K mutation acts as a viral determinant to block the
IFN-dependent antiviral pathway (Ashour et al., 2009; Liu et al., 2005;
Mazzon et al., 2009; Muñoz-Jordán et al., 2005).
Zoonotic WNV is present predominantly amongst avian hosts and
can infect humans through transmission via invertebrate vectors. A
single OAS gene has been identiﬁed in avian species (Tatsumi et al.,
2003; Yamamoto et al., 1998). Interestingly, the Val to Met substitution
at position 2K-9 was observed in a WNV-infected bird in a study of
phenotypic changes in North American WNV populations (Davis et al.,
2004). It has been recently reported that genetic variation in human
OAS1 is a risk factor for initial WNV infection (Lim et al., 2009).
Improved knowledge of the mechanisms by which the 2K peptide
restricts the OAS antiviral pathway will broaden understanding of how
viral and host genetic diversity inﬂuences WNV pathogenesis.
Materials and methods
Cells and viruses
BHK-21, HEK-293T and Vero cell lines were cultured in DMEM
medium(Invitrogen), supplementedwith 10%heat-inactivated fetal calf
serum (FCS) and 1% penicillin/streptomycin. The establishment ofMEF/
3T3.Tet-Off, MEF/3T3.Tet-Off/Oas1b, MEF/3T3.Tet-Off/Oas1bΔC-term
and MEF/3T3.Tet-Off/Oas1b/siRNA-82 cell lines was reported previ-
ously (Kajaste-Rudnitski et al., 2005). These cells are maintained in
DMEM/10% FCS/4 mM glutamine supplemented with 100 μg/ml G418
(Gibco, Invitrogen), 100 μg/ml Hygromycin (BD Biosciences Clontech)
and 100 ng/ml Tetracyclin (Sigma-Aldrich) as a repressor. Production of
the Israeli WNV strain IS-98-ST1 (GenBank accession number
AF481864) onmosquitoAedes pseudoscutellaris (AP61) cells, puriﬁcation
on sucrose gradients and virus titration by focus immunodetection assay
(FIA) were performed as previously described (Despres, Frenkiel, and
Deubel, 1993; Lucas et al., 2004). North American WNV strain NY99-
ﬂamingo 382-99 (GenBank accession no. AF196835) was generated
from an infectious cDNA clone as described below.
Generation of passaged WNV on Oas1b-expressing cells
WNV strain IS-98-ST1was sequentially passaged in induced (−Tet)
MEF/3T3.Tet-Off/Oas1b and MEF/3T3.Tet-Off/Oas1bΔC-term cells. Cell
monolayers in 25-cm2 ﬂaskswere infected for 3 days atMOI 1. Between
passages, viral titers were quantiﬁed by FIA (Despres et al., 1993). To
select for Oas1b-resistant WNV variants, induced MEF/3T3.Tet-Off/
Oas1b cells grown in Permanox Labtek chambers (Nalge Nunc
International) were infected with the passaged virus at MOI 0.1. Viral
replication in Oas1b-expressing cells was analyzed by immunoﬂuores-
cence assay 2 days p.i. using anti-WNV HMAF as previously described
(Lucas et al., 2003). After eight repeated passages, a single virus clone,
WN-Oas1bR, was selected on its capacity to counteract the antiviral
effect of Oas1b. WN-Oas1bR grown on AP61 cells was puriﬁed on
sucrose gradients as previously described (Despres et al., 1993). The
passage ofWNVonMEF/3T3.Tet-Off/Oas1bΔC-term cells was terminated
at passage 10 to generate the WN-Oas1bΔC-termP10 virus population.Sequencing of genomic RNA from WNV
Genomic RNA was extracted from highly puriﬁed WNV using the
NucleoSpin RNA II Kit (Macherey-Nagel). Genome-length RT-PCRwas
performed with the Titan One Tube RT-PCR kit (Roche Applied
Science) using a set of primers designed from the nucleotide sequence
of WNV IS-98-ST1. Sequencing reactions were performed using the
BigDye Terminator v3.1 cycle sequencing kit (Applied Biosystems)
and puriﬁed by ethanol precipitation. Sequence chromatograms from
both strands were obtained on automated sequence analyzers
(Applied Biosystems). Sequencing of the 5′- and 3′-end termini of
viral genomic RNA was performed by Rapid Ampliﬁcation of cDNA
ends (RACE). The nucleotide sequence of WN-Oas1bΔC-termP10 virus
was analyzed at positions where mutations occurred in WN-Oas1bR.
Generation of recombinant WNV
The construction of plasmids pWNNY99-1 and pWNNY99-2
representing a two-plasmid system for generation of infectious RNA
of North AmericanWNV strain NY99-ﬂamingo 382-99 from an in vitro
ligated cDNA template and recovery of infectious viruses from RNA
will be described elsewhere (Khromykh et al., manuscript in
preparation). Recovered viral supernatants were quantiﬁed by plaque
assays on BHK-21 cells and FIA on AP61 cells. The QuikChange XL Site-
Directed Mutagenesis Kit (Stratagene) was used to engineer nucle-
otide changes into the plasmids pWNNY99-1 and pWNNY99-2.
Presence of mutations into mutant NY99 viruses was veriﬁed by
sequencing as described above.
Construction of expression plasmids and their transfection
The 0.5-kbp synthetic genes encoding the WNV IS-98-ST1 NS4A-
2K and 2K-NS4B precursors with a Val or Met residue at position 2K-9
and ﬂanked by a HA tag at their 3′ ends were obtained from Genecust
Co. (Luxemburg). All viral sequences contained an exogenous ATG
start codon at their 5′ ends and a stop-codon at their 3′ ends. The
different NS4A-2K and 2K-NS4B constructs were inserted between
the unique BglII and EcoRI sites of the pIRES DsRed-Express vector
(BD Biosciences Clontech) expressing the autoﬂuorescent DsRed
protein under the control of an IRES promoter. Cells were transfected
using Fugene transfectant reagent (Roche Applied Science) according
to manufacturer's recommended procedure. Transfected cells were
visualized by DsRed expression.
Real-time RT-PCR
To prepare intracellular vRNA, total RNAwas extracted fromWNV-
infected cells using the NucleoSpin RNA II kit (Machery-Nagel)
according to manufacturer's recommended procedure. RT-PCR anal-
ysis of vRNA was performed using the QuantiTect SYBR Green RT-PCR
Kit (Qiagen) on a Lightcycler 2.0 Real-TimePCRSystem(RocheApplied
Science). The primers for WNV E gene were 5′-WNE-F (5′-TCAGC-
GATCTCTCCACCAAAG-3′) and 3′-WNE-R (5′-GGGTCAGCACGTTTGT-
CATTG-3′). Ribosomal 18S RNA (rRNA) was used as a house-keeping
sequence control for the normalization of samples using the 2−ΔΔCt
method (Livak and Schmittgen, 2001). To quantitate the differences in
vRNA production, the relative level of vRNA in reference samples was
assigned a value of 1 (Kajaste-Rudnitski et al., 2005).
Immunoblot assay
Cellular proteins were analyzed by immunoblotting as previously
described (Kajaste-Rudnitski et al., 2005). Cells were lysed with
Nonidet P-40 lysis buffer (20 mM Tris–HCl, pH 8.0, 100 mM NaCl,
1 mM EDTA, 0.5% NP-40) containing a mixture of protease inhibitor
(Roche Applied Science). Samples were separated on a 4–12% Bis–Tris
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monoclonal 4G2 antibody, which is speciﬁc for ﬂavivirus E proteins. A
goat anti-mouse peroxidase-conjugated IgG (Thermo Fisher Scientiﬁc
Inc.) was used as secondary antibody. β-Actin expression was
detected using a mouse monoclonal β-actin antibody (Sigma-
Aldrich). HA-tagged proteins were detected using peroxidase-conju-
gated rat mAb speciﬁc to the HA epitope (Roche Applied Science).
Expression and puriﬁcation of the NS3 NTPase/helicase domain
TheWNV cDNAs encoding the NS3 NTPase/helicase domain (NS3-
182 to NS3-619) were cloned into the pET-DEST42 Gateway
expression vector (Invitrogen). Plasmids were transformed into E.
coli BL21 (DE3) One Shot cells (Invitrogen). Cultures were grown in
1 L Luria broth (LB) supplemented with 50 μg/ml ampicillin at 37 °C
until the OD600 reached 0.6. Expression was induced with 0.5 mM
isopropyl-β-thiogalactopyranoside (IPTG) and cultures were grown
for an additional 16 h at 22 °C. All puriﬁcation steps were carried out
at 4 °C. The bacteria were harvested by centrifugation, pellets were
resuspended in 100 ml lysis buffer (20 mM Tris–HCl, pH 8.0, 0.5 M
NaCl) containing 0.75 mg/ml lysozyme and incubated for 30 min.
Bacteria were disrupted by sonication (cycles of 30 s for 10 min). The
soluble extracts were centrifuged at 8000×g at 4 °C for 15 min. The
supernatants were applied to 2-ml columns of TALON Metal Afﬁnity
Resin (BD Biosciences Clontech), washed with 20 mM Tris–HCl, pH 8,
0.5 M NaCl containing 10 mM imidazole and eluted with 20 mM Tris–
Hcl, pH 7, 0.5 M NaCl containing 300 mM imidazole. The recovered
proteins were further puriﬁed by gel-ﬁltration chromatography in
20 mM Tris–HCl, pH 7.5, 0.2 M NaCl and stored at−80 °C. Purity was
assessed by Coomassie blue staining of 4–12% SDS–PAGE, and
speciﬁcity was veriﬁed by immunoblotting using an antibody against
the V5 epitope (eBioscience, Inc.).
ATPase activity
Recombinant NS3 NTPase/helicase preparations were tested for
ATPase activity using the Malachite Green Phosphate Detection Kit
(R&D Biosystems, Inc.), measuring the amount of inorganic phosphate
in solution. Protein concentration was obtained from absorbance at
280 nm. Fifty nanomolar of helicase was incubated in a standard
buffer (50 mM Tris–HCl at pH 7, 2 mM MgCl2, 1.5 mM DTT, 0.5%
Tween 20) and various amounts (1–10 mM) of ATP at room
temperature (RT). KH2PO4 standards were used to convert absor-
bance at 620 nm to inorganic phosphate concentrations. The kinetics
of ATP hydrolysis followed the standard Michaelis–Menten model. Km
was calculated using the GraphPad Prism software.
Immunoﬂuorescence assay
Cells were ﬁxed with 3.2% paraformaldehyde (PFA) in PBS for
20 min and permeabilized with Triton X-100 in PBS for 4 min. Cells
were stained with antibodies in PBS/0.2% gelatin at 37 °C for 30 min.
FITC-conjugated rat mAb speciﬁc to the HA epitope (Roche Applied
Science) was used to detect the HA-tagged proteins. ER marker
Calreticulin was detected using rabbit polyclonal anti-Calreticulin
antibody (Abcam) and Cy-5-conjugated donkey anti-rabbit IgG
(Jackson ImmunoResearch Laboratories, Inc.). The samples were
mounted in Vectashield medium with DAPI (Vector Laboratories)
and ﬂuorescence images were taken with an Axiovert 200 M inverted
microscope (Zeiss).
Heparin–sepharose binding assays
The heparin–sepharose binding assay was performed as described
by Lee et al. (2004). Brieﬂy, virus was incubated with heparin–
sepharose or protein A–sepharose (Amersham Biosciences) in HBSS–BSA buffer (10 mM HEPES, pH 8.0, 0.2% BSA) at 4 °C overnight under
continuous shaking. Virus particles bound to sepharose–HBSS–BSA
mixtures were centrifuged at 4 °C for 5 minutes at 6000×g . The
supernatant containing the unbound viral fraction was used for FIA.Acknowledgments
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